The policy environment for rare disease and orphan medicines is complex and encompasses regulation, reimbursement, and ...

Last week, researchers from across the UK and Ireland met at Holborn’s Conway Hall for a day of stimulating presentations and ...

Dimitrios is an economist and his research interests lie in the fields of the economics of innovation and specifically on the economics of pharmaceutical markets and R&D. In addition, he is interested ...

Hannah joined OHE as an Economist in September 2024. She holds an MPharm degree from the University of Nottingham and an MSc in Health Economics and Health Policy from the University of Birmingham. As ...

Dr Seán Byrne is Senior Manager, Legal & Regulatory Affairs for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Seán represents EUCOPE members at relevant European Medicines ...

Dr. Inmaculada (Inma) Hernandez is a Professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hernandez is a pharmacist and a scholar whose ...

Thomas Allvin is Executive Director for Strategy and Healthcare Systems at the European Federation of Pharmaceutical Industries and Associations (EFPIA), where his responsibilities include overall ...

Luigi Siciliani is a Professor of Health Economics at the Department of Economics and Related Studies at the University of York, where he directs the MSc in Health Economics. He is currently an Editor ...

Michael Drummond is Professor Emeritus and former Director of the Centre for Health Economics at the University of York in the United Kingdom. His main field of interest is in the economic evaluation ...

Christopher Henshall Ph.D. has worked in universities, research funding bodies and the UK Civil Service, including positions at the UK Medical Research Council, the Department of Health and the NHS in ...

2024 marked OHE’s second year running the Policy Prize –a prize fund of £40,000 with the goal of moving the needle towards wider thinking about global solutions for the most pressing health economic ...

Notes: results ‘per person’ comprise all people with asthma in the UK,; results ‘per year’ comprise all people using pMDIs (not limited to asthma). In relation to our secondary aim of exploring the ...